Skip to Content


Active Substance: interferon alfacon-1
Common Name: interferon alfacon-1
ATC Code: L03AB09
Marketing Authorisation Holder: Astellas Pharma Europe B.V.
Active Substance: interferon alfacon-1
Status: Withdrawn
Authorisation Date: 1999-02-01
Therapeutic Area: Hepatitis C, Chronic
Pharmacotherapeutic Group: Immunostimulants

Therapeutic Indication

Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.
Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin.

The marketing authorisation for Infergen has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.